Cargando…

Immune evasive human islet-like organoids ameliorate diabetes

While stem cell-derived islets hold promise as a therapy for insulin-dependent diabetes, challenges remain in achieving this goal(1–6). Here we generate human islet-like organoids (HILOs) from induced pluripotent stem cells (iPSCs) and show that non-canonical WNT4 signaling drives the metabolic matu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshihara, Eiji, O’Connor, Carolyn, Gasser, Emanuel, Wei, Zong, Oh, Tae Gyu, Tseng, Tiffany W., Wang, Dan, Cayabyab, Fritz, Dai, Yang, Yu, Ruth T., Liddle, Christopher, Atkins, Annette R., Downes, Michael, Evans, Ronald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872080/
https://www.ncbi.nlm.nih.gov/pubmed/32814902
http://dx.doi.org/10.1038/s41586-020-2631-z
Descripción
Sumario:While stem cell-derived islets hold promise as a therapy for insulin-dependent diabetes, challenges remain in achieving this goal(1–6). Here we generate human islet-like organoids (HILOs) from induced pluripotent stem cells (iPSCs) and show that non-canonical WNT4 signaling drives the metabolic maturation necessary for robust ex vivo glucose-stimulated insulin secretion. These functionally mature HILOs contain endocrine-like cell types that, upon transplantation, rapidly re-establish glucose homeostasis in diabetic NOD-SCID mice. Overexpression of the immune checkpoint protein PD-L1 protected HILO xenografts such that they were able to restore glucose homeostasis in immune-competent diabetic mice for 50 days. Furthermore, ex vivo interferon gamma stimulation induced endogenous PD-L1 expression and restricted T cell activation and graft rejection. The generation of glucose-responsive islet-like organoids able to avoid immune detection provides a promising alternative to cadaveric and device-dependent therapies in the treatment of diabetes.